Selling a Medical Practice: Tax Treatment, Valuation, and Regulatory Compliance (2026)

Physician practice M&A is one of the most active segments in the lower middle market — hospital systems and private equity have been acquiring practices at an accelerating pace since 2020. But selling a medical practice involves tax and regulatory traps that most M&A advisors miss. Here is what the planning looks like when done correctly.

Physician practice M&A landscape

The physician practice acquisition market in 2026 is dominated by two buyer types with fundamentally different economics and deal structures.

Hospital systems and health networks

Hospital systems acquire practices primarily to capture downstream referral value — the diagnostic imaging, lab, inpatient procedures, and specialist referrals that flow from an employed primary care or specialist physician. This downstream value often exceeds the operating value of the practice itself, which is why hospitals historically paid prices for practices that seemed to defy conventional EBITDA multiple analysis.

Important considerations with hospital buyers:

• Compensation constraints. Post-acquisition physician compensation must be supported by an independent fair market value (FMV) opinion — the hospital's legal compliance team will require one. Compensation above FMV (including any element that reflects referral volume) creates Anti-Kickback and Stark Law exposure. See the regulatory section below.
• Employment agreements are standard. Hospital acquisitions almost universally require the selling physician to sign a 3–5 year employment agreement. The purchase price is partly for the practice assets and partly for the locked-in future services. The structure of this agreement — compensation method, productivity incentive, and non-compete terms — has major tax and personal planning implications.
• Asset purchase structure is common. Most hospital acquisitions are structured as asset purchases rather than stock acquisitions. Hospitals prefer to acquire specific assets and assume specific liabilities, avoiding any exposure to the practice entity's historical compliance obligations.

Private equity and DSO-equivalent platforms

Private equity has been aggressively building physician roll-up platforms across virtually every specialty since 2018. Dermatology, gastroenterology, orthopedics, behavioral health, primary care, and ophthalmology all have active PE roll-up ecosystems. PE platforms typically offer:

• Higher EBITDA multiples than hospital buyers in many specialties (because PE is buying operating cash flow, not referral capture)
• PE rollover equity opportunity — keeping 15–30% in the platform for the second bite when the PE firm exits. See our PE rollover equity guide for the tax deferral mechanics and second-bite math.
• Greater operating autonomy in some arrangements — physicians retain clinical control while PE handles billing, HR, and real estate
• Faster deal process — PE buyers move more efficiently than hospital M&A committees

Other physician groups and strategic acquirers

Larger physician-owned groups, multi-specialty practices, and integrated health systems represent a third buyer category. These transactions are often the most straightforward from a regulatory standpoint — physician-to-physician transactions have no Stark Law referral exposure — but typically pay lower prices than PE or hospital buyers because they lack the referral-capture premium or PE leverage.

Valuation by specialty

Physician practices are typically valued using a combination of EBITDA multiples (for PE buyers) and revenue multiples (for hospital buyers assessing referral value). The ranges below reflect lower-middle-market transactions in 2026 for PE-type buyers; hospital multiples can vary significantly based on the specific health system's referral economics.

Ranges reflect arms-length lower-middle-market transactions. Actual multiples depend on practice size, payer mix, provider count, geographic market, ancillary revenue, and buyer type. A quality-of-earnings report normalizes EBITDA for owner compensation and one-time items before buyers apply their multiple. See our QoE guide.

What compresses physician practice multiples

• Single-physician practices. A practice built entirely on one physician's patient relationships and clinical reputation has minimal enterprise value beyond the physician's continued employment. Buyers price this as the present value of that physician's incremental production — which is far less than a multi-physician group with institutional relationships.
• Medicare/Medicaid heavy payer mix. Government payer concentration creates reimbursement risk, coding compliance exposure, and lower margin versus commercial payers. PE buyers discount practices above 50–60% Medicare/Medicaid mix.
• No ancillary revenue. Practices that generate revenue only from professional services — with no in-house imaging, lab, ASC, or dispensing — have lower EBITDA and fewer assets for PE to leverage.
• Compliance history. Any history of government investigations, RAC audits with significant overpayment findings, or False Claims Act exposure creates a compliance liability that buyers price in aggressively or use to walk away.

QSBS: health professions are excluded

This is the most important planning difference between a physician practice sale and a manufacturing or technology company sale. IRC §1202(e)(3)(A) explicitly excludes "health" from the definition of a Qualified Small Business.¹ A medical practice — regardless of its entity structure, size, or profitability — cannot issue Qualified Small Business Stock. Physicians who hold C-corp stock in their practice entity cannot exclude any gain under §1202, regardless of how long they have held it.

This means the $15M federal exclusion available to manufacturing, technology, and many other business owners after the OBBBA (One Big Beautiful Bill Act, July 2025) simply does not apply to physicians. On a $10M sale, that exclusion would have been worth up to $2.38M in avoided federal tax (23.8% on $10M). Physicians must plan around its absence.

Personal goodwill: the physician's primary tax tool

Personal goodwill is the value attributable to an individual's unique skills, reputation, relationships, and expertise — as distinct from the enterprise goodwill of the business itself. In a medical practice, a substantial portion of what a buyer is paying for is precisely this: the physician's patient relationships, clinical reputation, specialist referral network, and the trust that keeps patients returning year after year.

When personal goodwill is properly documented and separately allocated in the purchase agreement, it is taxed as long-term capital gain at the individual level (23.8% federal top rate) rather than as ordinary income flowing through an entity sale (up to 37%). On a $5M goodwill allocation, the tax difference is approximately $660,000.²

How personal goodwill works in a practice sale

In an asset sale of a medical practice, the buyer and seller agree to allocate the total purchase price across asset classes on Form 8594. The allocation typically includes:

• Equipment and furnishings (§1245 recapture at ordinary income rates on the depreciation taken)
• Patient charts and records (ordinary income — customer-based intangibles, Class VI)
• Trade name and enterprise goodwill (capital gain, §1231 asset)
• Non-compete agreement (ordinary income, Class VI)
• Personal goodwill of the physician-seller (capital gain to the individual, bypasses the practice entity entirely)

The critical mechanic: personal goodwill is sold directly by the physician to the buyer, not by the practice entity. Because it never passes through the entity, it avoids double taxation in C-corps, it is not subject to the entity's ordinary income characterization, and it is taxed as LTCG in the physician's hands. See our personal goodwill guide for the case law foundation (Martin Ice Cream, Muskat) and documentation requirements.

Documentation requirements for physician personal goodwill

The IRS does not recognize personal goodwill claims that are made without contemporaneous documentation. To support a personal goodwill allocation in a medical practice sale, physicians should have — ideally before the process begins:

1. No non-compete with the practice entity. If the physician has a pre-existing employment or shareholder agreement that includes a non-compete, the argument that the physician's patient relationships are theirs to sell is weakened — those relationships were "owned" by the entity during the non-compete period. This is one of the most common documentation mistakes physicians make.
2. Independent professional reputation. Speaking engagements, published research, professional society leadership, or other evidence that the physician's reputation extends beyond the practice entity strengthens the personal goodwill argument.
3. FMV appraisal. An independent valuation of the personal goodwill component — separate from enterprise goodwill — helps substantiate the allocation and withstands IRS scrutiny.
4. Separate allocation in the purchase agreement. The buyer must agree to separately allocate and pay for personal goodwill. Many hospital buyers are reluctant because the payment is to the individual, not the entity, and can create its own compensation compliance complexity. PE buyers are often more flexible.

Asset sale vs. stock sale for medical practices

Most medical practice acquisitions are structured as asset sales. Hospital buyers almost universally insist on it — they want to acquire specific assets and exclude historical liabilities including any hidden compliance exposure. PE buyers also tend to prefer assets for similar reasons, particularly in specialties with meaningful government payer billing.

What this means for the seller:

The key insight: in most industries, the seller prefers stock sale (avoids recapture, simpler). In a medical practice, the asset sale may actually be preferable for the seller — because the personal goodwill allocation mechanism only works in an asset sale, and that allocation can save far more in taxes than stock sale simplicity would.

Stark Law, Anti-Kickback Statute, and FMV requirements

Healthcare transactions are governed by federal fraud and abuse laws that have no equivalent in any other industry. Every physician practice acquisition must be structured to comply with them, or risk post-close enforcement exposure that can dwarf the deal economics.

The Stark Law (42 U.S.C. §1395nn)

The Stark Law prohibits a physician from making referrals for "designated health services" (DHS — including inpatient and outpatient hospital services, imaging, lab, home health, and others) to an entity with which the physician has a financial relationship — unless a specific exception applies.³

In a practice acquisition, the financial relationship is the employment or services arrangement the physician enters post-closing. To fall within the Stark employment exception, the compensation arrangement must:

• Be for bona fide employment services
• Reflect fair market value for the physician's services — as determined by an independent FMV opinion
• Not take into account, directly or indirectly, the volume or value of any referrals by the physician to the employer
• Be commercially reasonable even if the physician made no DHS referrals

The FMV opinion is not optional — it is the key compliance document for every hospital and health system acquirer. The physician's post-acquisition compensation is set to what an independent physician compensation valuation firm (MGMA, SullivanCotter, Gallagher, or similar) determines is fair market value for services in that specialty and geography. If the compensation is set above FMV — even at the physician's request — the entire arrangement may fall outside the Stark exception.

The Anti-Kickback Statute (42 U.S.C. §1320a-7b(b))

The AKS prohibits knowingly and willfully offering, paying, soliciting, or receiving anything of value to induce or reward referrals of items or services covered by federal healthcare programs.⁴ The purchase price in a practice acquisition must reflect the FMV of the practice's assets — not the value of anticipated future referrals. An above-FMV purchase price can be characterized as a kickback for future Medicare/Medicaid referrals.

OIG guidance and safe harbors

The Department of Health and Human Services Office of Inspector General (OIG) has published guidance on practice acquisitions and physician compensation arrangements over many years. The 2020 Stark Law final rule (85 Fed. Reg. 77492) and accompanying AKS safe harbor updates provided additional clarity on value-based care arrangements and compensation flexibility — but the core FMV requirement remains unchanged.⁵

RVU-based earnouts: structure and tax treatment

Most physician practice acquisitions include some form of performance-based compensation that functions as an earnout. Rather than a classic M&A earnout tied to EBITDA or revenue targets, physician earnouts are typically structured around RVU (Relative Value Unit) production — the Medicare-defined measure of physician work output.

Why RVU is the standard metric

RVU-based compensation is the most defensible post-acquisition physician pay structure from a Stark Law compliance standpoint. Because RVUs measure the physician's own clinical work — not the volume of referrals to the acquiring entity — an RVU-based bonus does not, by its nature, reflect referral volume. This is why virtually every hospital-employed physician contract since 2010 uses some form of wRVU (work RVU) production incentive.

Tax treatment of RVU earnouts

This is where the physician's deal structuring advisor earns their fee. The tax treatment of post-sale payments to a physician depends entirely on how those payments are characterized:

• Ordinary income (up to 37%): Post-acquisition RVU productivity compensation is employment income — W-2 wages, subject to ordinary income tax rates and FICA (Social Security and Medicare taxes).
• Capital gain (23.8%): If a portion of the purchase price is genuinely contingent on future practice performance and meets the IRC §453 contingent installment payment requirements, it may be taxed as capital gain at LTCG rates. The Temp. Reg. §15a.453-1(c) framework governs contingent installment payments — there are three scenarios (fixed maximum selling price, fixed payment period, no cap or fixed term). See our earnout guide for the full tax treatment analysis.

The characterization test: if the buyer is paying for future services, the payment is compensation. If the buyer is paying for the established practice value on a contingent measurement basis, it may be capital gain. Hospital buyers will typically characterize post-close RVU payments as compensation (because that satisfies Stark compliance). PE buyers may have more flexibility to structure a portion as true earnout capital gain — but this requires careful structuring upfront, separate from the employment agreement.

Medicare and Medicaid contract assignment

A medical practice's payer contracts — most importantly its Medicare enrollment and group billing credentials — cannot be simply assigned to an acquirer in the same way that a software license or commercial contract can. Each provider must be independently enrolled in Medicare, and group enrollment is tied to the specific legal entity.

What happens in an asset sale

In an asset sale, the acquiring entity is a new or different legal entity from the selling practice. The buyer must:

• Complete a new Medicare enrollment application (Form CMS-855B for organizational providers, or reassignment on Form CMS-855R for individual physicians joining a group)
• Obtain a new Group NPI (National Provider Identifier) if the acquiring entity is new
• Establish new Medicaid enrollment in each state separately — Medicaid is administered by states and has no universal assignment process
• Renegotiate commercial payer contracts — most major commercial payers require credentialing and contracting with the new entity rather than accepting assignment of the prior entity's rates

This process takes time — typically 60–180 days for Medicare credentialing, and potentially longer for Medicaid and commercial payers. During this window, the practice may have limited billing capability for government payer patients. Buyers and sellers typically address this through a transition services agreement (TSA) or billing services arrangement that allows the seller entity to continue billing on the buyer's behalf while the new enrollment is processed.

Change of ownership considerations

CMS has specific rules governing Medicare provider enrollment changes in a change of ownership (CHOW) transaction. In a stock sale, where the provider entity continues to exist under new ownership, the existing Medicare enrollment and Conditions of Participation may survive the transaction — but the buyer accepts all liability for the acquired entity's prior billing history, including any pre-existing overpayments or compliance issues CMS discovers later.

Malpractice tail insurance at closing

Physicians typically carry claims-made malpractice insurance — a policy that covers only claims filed while the policy is active. When a physician leaves the practice at closing, the claims-made policy does not cover claims filed after the physician's departure, even for incidents that occurred while the policy was in force.

Tail insurance (also called extended reporting period or ERP coverage) extends the reporting window — typically 5 years for most specialties, longer for OB/GYN and surgical specialties with longer claim latency. Tail premiums are typically 100–200% of the prior year's annual premium. For a physician paying $30,000/year in malpractice coverage, tail insurance at closing can cost $30,000–$60,000 or more.

Who pays is a negotiating point in every practice sale. Hospital buyers often agree to purchase tail coverage for acquired physicians — it is commercially reasonable and reduces the physician's post-close financial exposure. PE buyers may negotiate differently. Either way, the responsibility for tail coverage — and the cost allocation — must be explicitly addressed in the purchase agreement.

NIIT: active physician vs. passive investor treatment

The 3.8% Net Investment Income Tax (NIIT) applies to investment income — but not to income from a trade or business in which the taxpayer materially participates.⁶ Most practicing physicians easily satisfy the material participation tests (more than 500 hours per year in the activity). This means:

• A physician's share of practice income while actively working is not subject to NIIT under the §1411(c)(4) look-through rule for pass-through entities.
• The gain on sale of practice assets, if the physician materially participated in the year of sale, should also not be subject to NIIT — the §1411 regulations generally treat a materially participating owner's gain from a disposition of a pass-through interest as non-passive.

The NIIT analysis changes for a physician who has retired or significantly reduced clinical activity before the closing date. A physician who stopped practicing two years before a sale may be treated as a passive investor — subjecting the sale gain to the 3.8% surcharge. Timing the sale while still actively practicing matters for NIIT avoidance. See our NIIT guide for the complete material participation analysis.

Planning timeline: 2–5 years before a practice sale

4–5 years before sale: structure and pre-sale tax strategy

• Assess entity structure. Unlike manufacturing or technology companies, converting to a C-corp for QSBS provides no benefit for medical practices (health is excluded). However, entity structure still affects the §338(h)(10) election question and state tax treatment. An S-corp election may provide income tax benefits during the pre-sale period. See our S-corp vs. C-corp guide.
• Document personal goodwill. Remove any existing entity-level non-compete in your shareholder agreement. Build independent professional presence — publications, speaking, board positions. This documentation is the foundation of the personal goodwill allocation that can save hundreds of thousands at closing.
• Start a cash balance plan. Physicians typically have high earnings and can reduce AGI by $150,000–$290,000+ per year through a cash balance plan paired with a 401(k), depending on age and plan design. A physician owner aged 55–63 in 2026 can contribute aggressively in the years before sale. See our cash balance plan guide.⁷
• Estate planning window. The OBBBA permanently set the estate and gift tax exemption at $15M per person.⁸ GRATs and IDGTs funded with practice equity before a sale can shift the appreciation to heirs. See our estate planning before sale guide.

2–3 years before sale: value and marketability

• Reduce owner-dependency. Hire or develop associate physicians who can handle patient volume independently. A practice that runs without the founding physician's daily presence commands a higher multiple — and is more likely to retain patients post-transition, which is what the buyer is ultimately paying for.
• Ancillary revenue. Adding in-house diagnostic capabilities (ultrasound, DEXA, pulmonary function testing in primary care; anesthesia, pathology, or physical therapy ownership in surgical specialties) meaningfully increases EBITDA and the asset base a buyer can leverage. Each ancillary revenue dollar creates multiple expansion.
• Build a compliance program. Buyers conduct healthcare compliance diligence — coding audits, OIG exclusion checks, HIPAA policies, billing documentation. A practice that can present a functional compliance program reduces buyer concern and post-close holdback requirements.

12–18 months before sale: deal preparation

• Commission a sell-side QoE. A quality-of-earnings analysis by a third-party accountant normalizes EBITDA for owner compensation, medical director fees, personal vehicle expenses, one-time items, and below/above-market management services agreements. See our QoE guide.
• Engage an exit-planning financial advisor. The personal goodwill allocation, installment sale election, CRT feasibility, IRMAA analysis, and post-close portfolio construction need to be modeled before you receive the LOI — not after you sign it. An M&A attorney handles the transaction. A fee-only exit-planning advisor handles the financial consequences — including the $2M–$3M+ decisions that happen before and after the deal.
• Consider a CRT. If you hold appreciated equity in the practice entity and a CRT makes charitable planning sense, the binding commitment rule (Rev. Rul. 78-197) means the contribution must happen before the sale is legally committed. A CRT funded before LOI signing avoids capital gains on the contributed stock and generates a partial income tax deduction. See our CRT guide.

What an advisor models for a physician practice sale

A fee-only exit-planning advisor working on a physician practice sale typically runs analyses that fall entirely outside the scope of the M&A attorney and investment banker:

1. Personal goodwill vs. enterprise goodwill allocation. How much of the purchase price can defensibly be allocated to personal goodwill, and what does that allocation save in tax versus a standard asset allocation? Our business exit after-tax calculator can model the structure comparison.
2. Employment agreement tax analysis. Is the post-close compensation arrangement structured as capital-gain earnout or ordinary-income employment income? What does this mean for the physician's effective tax rate over the 3–5 year employment term?
3. IRMAA and Medicare premium exposure. A $5M+ practice sale almost certainly pushes the physician's MAGI into the top IRMAA tier for 2 years, adding up to $13,872 per person in Medicare surcharges. What strategies — installment sale, CRT, DAF — reduce the MAGI impact? See our IRMAA guide.
4. Installment sale election. If the gain not covered by personal goodwill is significant, a §453 installment sale that defers recognition over 3–7 years may reduce the total tax bill by keeping income below bracket thresholds. See our installment sale calculator.
5. Post-sale income transition. Practice income ends on closing day. The estimated tax safe harbor (110% of prior-year AGI), Roth conversion window during lower-income years, and portfolio construction from a large liquidity event all need to be planned before the wire arrives. See our post-sale planning guide.